Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01288222 · ClinicalTrials.gov registry record · NA

Selecting a Favorable KIR Donor in Unrelated HCT for AML

A NA study of Acute Myelogenous Leukemia, sponsored by Masonic Cancer Center, University of Minnesota.

Completed
Registry status
NA
Development phase
506
Enrollment target
19
Study locations

NCT01288222 is a NA study of Acute Myelogenous Leukemia that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 506 participants, above the 127-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (298% higher). The trial reports 19 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01288222, a NA study of Acute Myelogenous Leukemia, has completed, sponsored by Masonic Cancer Center, University of Minnesota.

COMPLETED
Registry status
NA
Development phase
506 participants
Enrollment target
19
Study locations

Study Summary

Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically, donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect. This study proposes to prospectively test and validate the utility and effectiveness of further informing URD identification and selection by KIR genotyping as a supplement to HLA matching and the other variables known or suspected to indicate the best URD for a patient. Hypotheses: 1. Favorable KIR donors will improve protection against relapse and improve leukemia free survival (LFS) after URD HCT for AML. 2. Directed study procedures for rapid KIR genotyping and reporting to searching Transplant Centers (TC) can inform donor search and selection without delay in donor availability for HCT.

Conditions Studied

Acute Myelogenous Leukemia

Interventions

  • OTHER KIR genotype

Study Locations (19)

Texas

  • Baylor Sammons Cancer Center - Dallas
  • M.D. Anderson Cancer Center - Houston
  • Methodist Healthcare System of San Antonio - San Antonio

Minnesota

  • Masonic Cancer Center, University of Minnesota - Minneapolis
  • Mayo Clinic Cancer Center - Rochester

New York

  • Roswell Park Cancer Institute - Buffalo
  • New York Presbyterian Weill Cornell Medical Center - New York

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio State University Comprehensive Cancer Center - Columbus

Arizona

  • Mayo Clinic - Scottsdale - Scottsdale

Colorado

  • Colorado Blood Cancer Institute - Denver

Georgia

  • Emory University - Atlanta

Illinois

  • University of Chicago Medical Center Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 506 participants
Start Date 2011-06
Est. Completion 2020-04
Phase NA

Sponsor

Masonic Cancer Center, University of Minnesota

249 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01288222

The ClinicalTrials.gov registry entry for NCT01288222 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (298% higher). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which KIR genotype is the first listed.

NCT01288222 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Texas, Minnesota, New York.

Frequently Asked Questions

What is clinical trial NCT01288222 about?

NCT01288222 is a clinical study titled "Selecting a Favorable KIR Donor in Unrelated HCT for AML". Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically, donors with more KIR B gene c...

What is the current status of trial NCT01288222?

This trial is currently completed. It is a NA study. The enrollment target is 506 participants. The study started on 2011-06. Estimated completion is 2020-04.

What conditions does trial NCT01288222 study?

This clinical trial studies the following conditions: Acute Myelogenous Leukemia.

What interventions are being tested in trial NCT01288222?

The interventions under investigation include: KIR genotype (OTHER).

Who is sponsoring clinical trial NCT01288222?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01288222 being conducted?

This trial has 19 study locations across Arizona, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myelogenous Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myelogenous Leukemia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.